Investor Overview


About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Recent News

National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer  -  1/15/2020
Pivotal Study of 1500 Patients Could Lead to Change in Practice Guidelines SAN CARLOS, Calif. , Jan. 15, 2020 /PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan , a prospective, More »
Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx  -  1/13/2020
Adds to Natera's Extensive Suite of More Than 200 Issued and Pending Patents SAN CARLOS, Calif. , Jan. 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S. More »
Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera™ Patients with Stage II-III Colorectal Cancer  -  1/9/2020
Study to quantify changes in post-surgical treatment and impact of early relapse detection using Signatera test SAN CARLOS, Calif. , Jan. 9, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called More »
Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference  -  1/8/2020
SAN CARLOS, Calif. , Jan. 8, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, More »
Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents  -  1/6/2020
Exceeds 2019 goal of $40-$50 million in cumulative contracts with pharmaceutical companies and extends leadership in ctDNA MRD SAN CARLOS, Calif. , Jan. 6, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of More »

Upcoming Events

More events are coming soon.

Past events

Wednesday, 01/15/20 at 10:00 AM PST

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.